Condition: Disease-free Survival · Sponsor: Shanghai Jiao Tong University School of Medicine
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
This description comes directly from the study's public registry record.
Jieling Jiang · +8613311986505 · jiangjieling66@hotmail.com
jiong HU · +8613764313546 · hj10709@rjh.com.cn
Always discuss trial participation with your own doctor first.
| Blood & Marrow Transplantation Center, RuiJin Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
| Shanghai No 6 Hospital | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05436561